CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date

Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key as...

Full description

Saved in:
Bibliographic Details
Published in:Blood 2016-06, Vol.127 (26), p.3312-3320
Main Authors: Park, Jae H., Geyer, Mark B., Brentjens, Renier J.
Format: Article
Language:English
Subjects:
Adoptive Transfer
Advances in Cell-Based Immune Therapeutics in Hematology
Animals
Antigens, CD19
B-Lymphocytes - metabolism
B-Lymphocytes - pathology
Hematologic Neoplasms - genetics
Hematologic Neoplasms - metabolism
Hematologic Neoplasms - therapy
Humans
Receptors, Antigen, T-Cell - genetics
Review Series
T-Lymphocytes - transplantation
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2016-02-629063